Savara Inc. Files 8-K with Regulatory Updates
Ticker: SVRA · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1160308
| Field | Detail |
|---|---|
| Company | Savara Inc (SVRA) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
TL;DR
Savara Inc. filed an 8-K on 6/26/24 covering Reg FD, other events, and financials.
AI Summary
On June 26, 2024, Savara Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements and exhibits. The company, formerly known as Mast Therapeutics, Inc., is incorporated in Delaware and its fiscal year ends on December 31st.
Why It Matters
This 8-K filing provides important updates and disclosures for Savara Inc. and its investors, potentially impacting the company's stock performance and regulatory standing.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report and does not appear to contain any immediate material adverse information.
Key Numbers
- 001-32157 — Commission File Number (Identifies the company's SEC filing history.)
- 84-1318182 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Savara Inc. (company) — Registrant
- Mast Therapeutics, Inc. (company) — Former Company Name
- June 26, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 1231 (date) — Fiscal Year End
FAQ
What specific events are covered under the 'Other Events' section of this 8-K filing?
The provided text does not specify the details of the 'Other Events' beyond listing it as an item in the 8-K.
What is the significance of the 'Regulation FD Disclosure' mentioned in the filing?
A Regulation FD Disclosure indicates that the company is making public disclosures of material non-public information to avoid selective disclosure.
When did Savara Inc. change its name from Mast Therapeutics, Inc.?
The filing indicates the former company name was Mast Therapeutics, Inc. and the date of name change was March 12, 2013.
What is Savara Inc.'s primary industry classification?
Savara Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where is Savara Inc. headquartered?
Savara Inc.'s business address is listed as 6836 Bee Cave Road, Building 3, Suite 201, Austin, TX 78746.
Filing Stats: 1,226 words · 5 min read · ~4 pages · Grade level 11.5 · Accepted 2024-06-26 06:40:01
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share SVRA The Nasdaq Global Se
Filing Documents
- d860197d8k.htm (8-K) — 59KB
- d860197dex991.htm (EX-99.1) — 44KB
- g860197page6.jpg (GRAPHIC) — 6KB
- 0001193125-24-168501.txt ( ) — 243KB
- svra-20240626.xsd (EX-101.SCH) — 3KB
- svra-20240626_lab.xml (EX-101.LAB) — 17KB
- svra-20240626_pre.xml (EX-101.PRE) — 11KB
- d860197d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Savara Inc. Press Release dated June 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 26, 2024 SAVARA INC. a Delaware corporation By: /s/ Dave Lowrance Dave Lowrance Chief Financial & Administrative Officer